Business
Spruce Biosciences Announces Acceptance of Abstract for Presentation at the Annual Meeting of the Endocrine Society (ENDO 2023)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and
About this update from Spruce Biosciences, Inc.
[{"type":"text","content":" SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nSpruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that a submitted abstract was accepted for the 105th Annual Meeting of the Endocrine Society (ENDO 2023) taking place June 15-18, 2023, in Chicago. In a poster presentation, the company will highlight the effect of tildacerfont on gonadotropins and testicular steroidogenesis in men with classic congenital adrenal hyperplasia (CAH).\n\n\nENDO 2023 presentation details are as follows:\n\n\nTitle: Effect of tildacerfont on gonadotropins and testicular steroidogenesis in men with classic 21-hydroxylase deficiency\nSession Title: P72 – Clinical Adrenal and Pituitary: Adrenal Insufficiency\nSession Date & Time: 1:00 p.m. – 2:00 p.m. CT on June 17, 2023\nPresenter: Will Charlton, M.D., M.A.S., Chief Medical Officer, Spruce Biosciences\nAuthors: Ahmed Khattab, M.D., Will Charlton, M.D., M.A.S., and Richard Auchus, M.D., Ph.D.\n\n\nThe poster will be available on the company’s website beginning June 17, 2023, at 2:00 p.m. CT. Access more information about ENDO 2023 here.\n\n\nAbout Spruce Biosciences\n\n\nSpruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Spruce is also developing tildacerfont for women suffering from polycystic ovary syndrome (PCOS) with primary adrenal androgen excess. To learn more, visit www.sprucebiosciences.com and follow us on Twitter @Spruce_Bio, LinkedIn, Facebook and YouTube.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20230612005110/en/\n\nMedia\nWill Zasadny\nEvoke Canale\n(619) 961-8848\[email protected]\[email protected]\n\n\nInvestors\nXuan Yang\nSolebury Strategic Communications\n(415) 971-9412\[email protected]\[email protected]\n\n\nSource: Spruce Biosciences, Inc.","length":6816,"tagName":"div"}]